CLAIMS

1. A pharmaceutical composition comprising Compound A and an excipient, wherein Compound A has the following structure:



(A),

wherein the amount of Compound A in the pharmaceutical composition is 1%-20%, preferably 2.5%-10%, more preferably 5%, by mass of the total composition.

2. The pharmaceutical composition according to claim 1, wherein the particle size distribution d(0.9) of Compound A is less than or equal to 150 μm, preferably less than or equal to 100 μm, more preferably less than or equal to 85 μm.

3. The pharmaceutical composition according to claim 1 or 2, wherein the excipient comprises a filler which is selected from one or more of lactose, microcrystalline cellulose, sucrose, glucose, powdered cellulose, calcium phosphate, calcium hydrogen phosphate, calcium carbonate, aluminum silicate, dextrin, starch, pregelatinized starch, sodium chloride, potassium chloride, mannitol, or sorbitol, preferably one or more of lactose, microcrystalline cellulose, or mannitol.

4 The pharmaceutical composition according to claim 3, wherein the filler is mannitol and microcrystalline cellulose, and the mass ratio of mannitol to microcrystalline cellulose is from 3:1 to 1:1, preferably 1:1.

5. The pharmaceutical composition according to any one of claims 1-4, wherein the excipient further comprises a disintegrant, wherein the disintegrant is one or more of starch, pregelatinized starch, sodium carboxymethyl starch, cross-linked povidone or croscarmellose sodium, preferably cross-linked povidone.

6. The pharmaceutical composition according to claim 5, wherein the amount of the cross-linked povidone is from 0.5% to 10%, preferably from 3% to 7%, more preferably 5%, by mass of the total composition.

7. The pharmaceutical composition according to any one of claims 1-6, wherein the excipient further comprises a lubricant, wherein

the lubricant is one or more of stearic acid, magnesium stearate, calcium stearate, aluminum stearate, palmitic acid, glyceryl behenate, polyethylene glycols with various molecular weights, hydrogenated castor oil, and sodium stearyl fumarate, preferably magnesium stearate.

8. The pharmaceutical composition according to claim 7, wherein the amount of magnesium

stearate is from 0.25% to 2%, preferably from 0.5% to 1.5%, more preferably 1%, by mass of the total composition.

9. The pharmaceutical composition according to any one of claims 1-8, wherein the dosage form of the pharmaceutical composition is tablet, capsule, granule or powders, preferably tablet.

10. The pharmaceutical composition according to claim 9, wherein the tablets further comprise a film coating layer; the tablet is coated with a gastric soluble film coating premix or a coating material, wherein the coating materials is selected from one or more of polyvinyl alcohol, hydroxypropyl methylcellulose, talc, polyethylene glycol, polyethylene glycol-polyvinyl alcohol copolymer, titanium dioxide, glyceryl mono- and dicaprylocaprate, and lake; preferably, the tablet is coated with a gastric soluble film coating premix; wherein the target coating weight gain is from 0.5% to 10%, preferably from 1% to 6%, more preferably from 2% to 4%, by mass of the tablet core.

11. A pharmaceutical composition according to any one of claims 1-9, wherein the pharmaceutical composition comprises Compound A, a filler, a lubricant, a disintegrant.

12. The pharmaceutical composition according to claim 11, wherein the amount of Compound A is 1%-20%, preferably 2.5%-10%, more preferably 5%, by mass of the total composition;

the amount of the filler is from 70% to 99%, preferably from 80% to 90%, more preferably 89%, by mass of the total composition;

the amount of the lubricant is from 0.25% to 2%, preferably from 0.5% to 1.5%, more preferably 1%, by mass of the total composition;

the amount of the disintegrant is from 0.5% to 10%, preferably from 3% to 7%, more preferably 5%, by mass of the total composition;

13. The pharmaceutical composition according to claim 11 or 12, wherein the pharmaceutical composition further comprise a film coating layer; wherein the target coating weight gain is from 0.5% to 10%, preferably from 1% to 6%, more preferably from 2% to 4%, by mass of the tablet composition core.

14. The pharmaceutical composition according to any one of claims 11-13, wherein the filler is mannitol and microcrystalline cellulose, and the mass ratio of mannitol to microcrystalline cellulose is from 3:1 to 1:1, preferably 1:1; the lubricant is magnesium stearate; the disintegrant is cross-linked povidone; the coating material is gastric soluble film coating premix.

15. The pharmaceutical composition according to any one of claims 1-14, wherein the unit dosage of the formulation is selected from 1 mg to 100 mg, preferably 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 75 mg, 100 mg, calculated based on the active Compound A.

16. The pharmaceutical composition according to any one of claims 1-15, wherein the unit

formulation of the pharmaceutical composition comprises 5 mg Compound A, 44.5 mg mannitol, 44.5 mg microcrystalline cellulose, 5 mg cross-linked povidone, 1 mg magnesium stearate, 3 mg coating powder; or the unit formulation of the pharmaceutical composition comprises 20 mg Compound A, 178 mg mannitol, 178 mg microcrystalline cellulose, 20 mg cross-linked povidone, 4 mg magnesium stearate, 12 mg coating powder.

17. A method for preparing the pharmaceutical composition according to any one of claims 1-16, wherein the preparation process is one or more of dry granulation process, wet granulation process, and direct powder compression process.

18. A method for preparing the pharmaceutical composition according to any one of claims 10-16, comprising the steps of:

(1) crushing Compound A;

(2) adding Compound A, a filler and a disintegrant into a mixer for premixing;

(3) adding a lubricant into the mixer and mixing thoroughly with the premixed powder; the mixture is compressed into a tablet, film-coated, and packaged.

19. Use of the pharmaceutical composition according to any one of claims 1-16 in the manufacture of a medicament for treating a disease associated with fibrotic bronchiectasis, and lower respiratory tract diseases caused by acute lung injury/acute respiratory distress syndrome.

20. The use according to claim 19, wherein the disease associated with fibrotic bronchiectasis is selected from non-cystic fibrotic bronchiectasis and cystic fibrotic bronchiectasis.

21. The pharmaceutical composition according to any one of claims 1-16 for use in treating non-cystic fibrotic bronchiectasis.